Linda Sherwood examines the latest developments in the treatment of resectable colorectal liver metastases, emphasising the need for a multidisciplinary approach
The liver is the most common site for colorectal cancer metastases. Surgical resection is the treatment of choice with encouraging five-year survival rates of 37-58%. All patients with hepatic disease should be reviewed by a liver surgeon to assess operability. Important factors in the pathway to potential liver resection include multidisciplinary team working to review imaging, determine resectability and consider the use of cytotoxics and monoclonal antibodies to optimise patient outcomes.
This article explores management of patients with colorectal liver metastases (CRLM) who are considered suitable for surgical resection. It draws on the epidemiology and changing context of treatment for this patient group. It covers the main features of the pathway to surgical resection and potential implications for those being considered for surgical resection.
Cancer Nursing Practice. 14, 8, 22-26. doi: 10.7748/cnp.14.8.22.s21Correspondence
This article has been subject to double-blind review and checked using antiplagiarism softwareConflict of interest
Received: 13 May 2015
Accepted: 24 August 2015
Alternatively, you can purchase access to this article for the next seven days. Buy now